News Release

HemogloBind™ Cited in Mass spectrometry-coupled Cellular Thermal Shift Assay (MS-CETSA) in Antimalarial Drug Study

MONMOUTH JUNCTION, NJ, June 11, 2025 -- Biotech Support Group reports on a journal article describing the simplicity and efficiency of HemogloBind™, to remove Hemoglobin prior to mass spectrometry-coupled cellular thermal shift assay (MS-CETSA) of red blood cells.

Go, Ka Diam, et al. "Antimalarial drug artemisinin stabilizes PfRACK1 binding to the ribosome." Structure (2025).

Artemisinin and its derivatives represent the core agents in artemisinin combination therapies that are the current frontline treatment for P. falciparum and P. vivax malaria infections. Artemisinins are known to bind a wide array of proteins that disrupt the parasite’s cellular physiology. Here, the study explored the artemisinins MOA by the mass spectrometry-coupled cellular thermal shift assay (MS-CETSA) of P. falciparum parasites, The article states “Hemoglobin depletion was performed for all isothermal dose response (ITDR) samples. 30 μL of HemogloBind resin, 30 μL of 20 mM potassium phosphate (pH 6.5) and 60 μL of each soluble fraction containing 300 μg proteins were mixed and vortexed for 10 s, followed by continuous rotation (15 min, 4°C) and a short centrifugation (9,000 rpm, 2 min, 4°C). Using the in-cell CETSA, the investigators identified 294 and 83 proteins that were thermo-stabilized and -destabilized upon 1 h exposure of P. falciparum parasites at the trophozoite stage. The CETSA-derived results in this study were dominated by disruptions of protein complexes, particularly those involved in the protein metabolism, including protein synthesis (e.g., Pf80S), protein folding (the T-complex), and protein turnover (both 19S and 26S proteasome complexes). The authors conclude that artemisinins stabilize the ribosome-PfRACK1 complex and ribosomal remodeling may aid parasite stress response to artemisinins

“This is an excellent example of how our Hemoglobin depletion product, HemogloBind™, contributed to proteome analysis of red cells, and that ultimately contributed to the conclusions of this study. Its very rewarding that from this study, the field can now see deeper insights into the mechanism of action of drugs targeting malaria.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

Click here for more information on HemogloBind™

Click here for more information on all of our Hemoglobin Removal products

Keywords: Hemoglobin depletion, HemogloBind™, malaria, Plasmodium falciparum, mass spectrometry-cellular thermal shift assay, MS-CETSA, artemisinin, antiplasmodial mode of action and drug resistance

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for expanding proteomic analysis. Following a tiered business strategy, the company continues its growth in the consumable research products area. For this market, key products include: AlbuVoid™ and AlbuSorb™ PLUS for albumin & IgG depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NRicher™ for low abundance and family specific, and targeted proteome enrichment. For more information, go to http://www.biotechsupportgroup.com

For business development contact: Matthew Kuruc
732-274-2866 mkuruc@biotechsupportgroup.com